189 related articles for article (PubMed ID: 8001119)
1. Transcriptional activation by p53 correlates with suppression of growth but not transformation.
Crook T; Marston NJ; Sara EA; Vousden KH
Cell; 1994 Dec; 79(5):817-27. PubMed ID: 8001119
[TBL] [Abstract][Full Text] [Related]
2. The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras.
Hansen RS; Braithwaite AW
Oncogene; 1996 Sep; 13(5):995-1007. PubMed ID: 8806689
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
Scian MJ; Stagliano KE; Deb D; Ellis MA; Carchman EH; Das A; Valerie K; Deb SP; Deb S
Oncogene; 2004 May; 23(25):4430-43. PubMed ID: 15077194
[TBL] [Abstract][Full Text] [Related]
4. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
[TBL] [Abstract][Full Text] [Related]
5. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan S; Ludwig RL; Haupt Y; Bates S; Lu X; Oren M; Vousden KH
EMBO J; 1996 Feb; 15(4):827-38. PubMed ID: 8631304
[TBL] [Abstract][Full Text] [Related]
6. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
7. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
Leiter LM; Chen J; Marathe T; Tanaka M; Dutta A
Oncogene; 1996 Jun; 12(12):2661-8. PubMed ID: 8700525
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
Preuss U; Kreutzfeld R; Scheidtmann KH
Int J Cancer; 2000 Oct; 88(2):162-71. PubMed ID: 11004663
[TBL] [Abstract][Full Text] [Related]
9. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
10. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth.
Pellegata NS; Cajot JF; Stanbridge EJ
Oncogene; 1995 Jul; 11(2):337-49. PubMed ID: 7624148
[TBL] [Abstract][Full Text] [Related]
11. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
12. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
Unger T; Mietz JA; Scheffner M; Yee CL; Howley PM
Mol Cell Biol; 1993 Sep; 13(9):5186-94. PubMed ID: 8355677
[TBL] [Abstract][Full Text] [Related]
13. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
14. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms.
Haupt Y; Rowan S; Shaulian E; Kazaz A; Vousden K; Oren M
Leukemia; 1997 Apr; 11 Suppl 3():337-9. PubMed ID: 9209383
[TBL] [Abstract][Full Text] [Related]
15. Sequence-specific transcriptional activation is essential for growth suppression by p53.
Pietenpol JA; Tokino T; Thiagalingam S; el-Deiry WS; Kinzler KW; Vogelstein B
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):1998-2002. PubMed ID: 8134338
[TBL] [Abstract][Full Text] [Related]
16. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
Selivanova G; Iotsova V; Okan I; Fritsche M; Ström M; Groner B; Grafström RC; Wiman KG
Nat Med; 1997 Jun; 3(6):632-8. PubMed ID: 9176489
[TBL] [Abstract][Full Text] [Related]
17. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
[TBL] [Abstract][Full Text] [Related]
18. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
19. Selective loss of endogenous p21waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins.
Tarunina M; Grimaldi M; Ruaro E; Pavlenko M; Schneider C; Jenkins JR
Oncogene; 1996 Aug; 13(3):589-98. PubMed ID: 8760300
[TBL] [Abstract][Full Text] [Related]
20. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
